Biliary glycoprotein (BGP) is the human homologue of a cell adhesion molecule (CAM) of the rat designated Cell-CAM. The BGP gene is a member of the carcinoembryonic antigen gene family, which belongs to the immunoglobulin superfamily. BGP is expressed in cells of epithelial and myeloid origin. In granulocytes, BGP is a main antigen of the CD66 cluster of differentiation antigens that mediate the binding to endothelial E-selectin. Since BGP is a major human
CAM, the expression of BGP was studied in 21 colorectal carcinoma tissue specimens and in the respective adjacent normal mucosae. As an internal control for epithelial mRNA, the expression of cytokeratin 18 was evaluated in parallel. In addition, the expression of carcinoembryonic antigen and nonspecific crossreacting antigen, which are highly homologous to BGP, was investigated. Two BGP mRNAs of3.9 and 1.5 kilobases were detected in the normal colonic mucosa samples. The median of the tumor-to-normal ratios of mRNA expression was 0.2 for both BGP mRNAs. In contrast, the median was 1.2 for cytokeratin, 1.0 for carcinoembryonic antigen, and 1.4 for nonspecific crossreacting antigen. Relative to cytokeratin 18 expression, the expression of BGP was reduced to sO.1 in half of the tumors and to s0.4 in >80% of the tumors. These rmdings indicate that the loss or reduced expression of the adhesion molecule BGP is a major event in colorectal carcinogenesis.
Cell adhesion molecules (CAMs) play a key role in the generation and maintenance of tissue architecture (1) . In comparison with normal tissues, malignant tumors are characterized by an altered phenotype and reduced intercellular binding forces. The loss of cell-cell binding, which closely correlates with differentiation and invasive potential of malignant tumors, is accompanied by a concomitant loss or altered expression of CAMs (2) . For example, in poorly differentiated prostatic carcinomas and squamous cell carcinomas of the head and neck, the expression of E-cadherin is reduced in comparison with well-differentiated tumors (3, 4) .
Biliary glycoprotein (BGP) is the human homologue of a CAM of the rat designated Cell-CAM (5-7). The designation "BGP" refers to a glycoprotein first described in human bile (8, 9) . Based on internal amino acid sequences of this glycoprotein, we previously identified a BGP cDNA clone in a normal human colon library (5) . The corresponding gene is a member of the carcinoembryonic antigen (CEA) family, which belongs to the immunoglobulin superfamily. BGP is expressed in cells of epithelial and myeloid origin (for review see ref. 10). After transfection into fibroblasts, the encoded protein mediates homophilic adhesion (11) . In contrast to other CAMs of the CEA family or immunoglobulin family
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such as the neural cell adhesion molecule (N-CAM), and similar to cadherins, cell adhesion mediated by BGP and its murine homologue is Ca2+ and temperature dependent (11, 12) . Thus, BGP combines structural features of the immunoglobulin superfamily with functional properties of the cadherin family of CAMs. Recently, we showed that BGP is the major antigen of the CD66 cluster of granulocyte differentiation antigens (13) . Antigens of the CD66 cluster mediate binding of granulocytes to endothelial E-selectin (14) .
In colonic carcinoma cell lines, several transcripts of the BGP gene have been identified (15) . Since we cloned the BGP gene from a normal colon cDNA library, the BGP gene should be expressed in normal colon as well. Therefore, we asked the question if the expression ofthis adhesion molecule differs between normal colonic mucosa and colonic carcinoma tissue. The expression of BGP was compared with the expression of CEA itself and of a major CEA-related glycoprotein, the so-called "nonspecific crossreacting antigen" (NCA) (for review, see ref. 10). We provide evidence that, in contrast to mRNAs coding for CEA and NCA, the expression of two BGP specific mRNAs is down-regulated in >80% of colorectal carcinomas when compared to the corresponding normal mucosa.
MATERIALS AND METHODS
Tissue Samples. Tissue samples from colorectal adenocarcinomas (n = 21) and the corresponding normal mucosae (n = 20) were studied. Tumor samples were obtained from surgically removed colorectal carcinomas. From each individual patient, normal mucosa was also prepared from the resection borders. For RNA preparation, normal and malignant tissues were immediately frozen in liquid nitrogen until processed.
Probes. For Northern blots, the following probes were used: (i) A 327-bp PCR fragment (nucleotide positions 1030-1356) (15) Fig. 2 , a graphical presentation of the tumor-to-normal ratios is given for the BGP mRNAs and the cytokeratin 18 mRNA. The medians of the tumor-to-normal ratios were 0.2 for both BGP-specific mRNAs and 1.2 for the cytokeratin 18 mRNA. From Table  1 and Fig. 2 it follows that, for cytokeratin, tumor-to-normal ratios were always >0.7. In contrast, the ratio was s0.5 in 17/21 (81%) for the 3.9-kb band and in 19/21 (90%) for the 1.5-kb band of the BGP-specific mRNAs. In contrast to BGP, the tumor-to-normal ratios were significantly higher for NCA. The median of 1.4 was slightly higher than the median for cytokeratin. The expression of CEA was highly variable (median = 1.0). When the distributions of tumor-to-normal expression was above 0.5 in 86%. When the normalized expression ofNCA is related to that of BGP, in all but 1 tumor BGP expression was <50% of NCA expression. For CEA, the relative expression varied in a wide range (0-4.2). BGP Expression and Lymph Node Involvement. Reduced levels of BGP were accompanied by a higher percentage of lymph node involvement. Lymph node metastases were present in 9/14 tumors (64%) with BGP mRNA tumor-tonormal ratio of <0.3 compared to only 1/7 (14%) with BGP ratios of >0.3 (3.9-kb mRNA, A2 probe) (P < 0.01, x2 test) (Fig. 4) . DISCUSSION BGP is a major human adhesion molecule. Since cell adhesion is altered in malignant tissues, the expression of BGPspecific mRNAs was investigated in colorectal carcinoma tissue specimens and in corresponding normal mucosa samples. For comparison, the expression of two additional members of the CEA family-e.g., CEA and NCA-was studied. Two BGP-specific mRNAs were down-regulated in >80o of colorectal carcinomas in comparison with the corresponding normal mucosa, whereas the expression of the NCA mRNAs was up-regulated in a number of tumors. The expression of CEA was highly variable.
Because CAMs guide tissue architecture, one must assume a close interrelationship between gene expression and histology (1) . For this reason we decided to avoid the use of cell lines and instead studied the expression of BGP-specific mRNA(s) in tissue samples of colonic carcinomas and adjacent normal colonic mucosae obtained during surgery. In several colonic cancer cell lines, the expression of two major BGP transcripts of 3.9 and 2.2 kb has been described (15) . In normal colonic mucosa and in a fraction of the carcinoma specimens, we found two transcripts of 3.9 and 1.5 kb using the A2 domain probe. The size of the 3.9-kb mRNA is consistent with the transcript expressed in the cell lines. However, the second transcript of 1.5 kb has not been found in colonic cancer cell lines. Although not formally proven, the presence of the A2 domain and the absence of the 3' UTR is reminiscent of BGP clone W211 described by Kuroki et al. (22) .
A major difficulty with tissue specimens is the variable proportion of epithelial and stromal tissue elements. To compensate for different proportions of epithelial tissue, the expression of a mRNA coding for cytokeratin 18 BGP is the human homologue of Cell-CAM, for which a cell adhesion function has been established by the use of antibodies blocking the aggregation of hepatocytes in vitro (24) . In line with this argument are transfection studies that show that human and murine BGPs are homophilic CAMs. In contrast to other CAMs of the immunoglobulin superfamily such as N-CAM, BGP shares functional properties with cadherins insofar as cell adhesion depends on Ca2+ and temperature (11, 12) . In contrast, CEA and NCA mediate homophilic and heterophilic cell adhesion in a Ca2+-and temperature-independent fashion after transfection of their cDNAs into fibroblasts (10), indicating a mechanism different from BGP. Moreover, the lack of transmembrane and cyto-A + plasmic domains in CEA and NCA and their strictly luminal localization argue against an intercellular adhesion function in normal colon epithelium in vivo (25, 26) . Since BGPspecific antibodies only became available very recently (13, 27) , the cellular localization of BGP is not determined so far. If BGP functions as CAM in normal colonic mucosa, one would expect that the reduction of BGP expression in tumors should be accompanied by a more invasive growth and an increased percentage of lymph node metastases. Indeed, a higher proportion of lymph node involvement was found in tumors with BGP mRNA tumor-to-normal ratios of c0.3. The fact that in about one-third of tumors with a relative BGP expression of <0.3 lymph node metastases were not detected may be due to the redundancy of CAMs. The loss of additional CAMs may be necessary for cancer cells to become overtly metastatic. One candidate is the putative CAM DCC (deleted in colorectal carcinomas) (28) . Furthermore, colorectal cancer cells may have to adopt new adhesion molecules for the establishment of metastases. As has been shown recently, a splice variant of CD44, which conferred the metastatic phenotype to a pancreatic carcinoma cell line of the rat, is expressed in a high percentage of human colorectal carcinomas. It has been proposed that the CD44 variant mediates the adherence of carcinoma cells to cellular elements in lymph nodes (29, 30) .
The frequency of the down-regulation of BGP is comparable with the frequency of major genetic alteration in colorectal cancer such as mutations of the p53 (31, 32) , RAS (33) , and APC (34) genes. At present, one can only speculate on the molecular mechanism underlying the down-regulation of BGP and the concomitant up-regulation of NCA expression. Since the NCA gene is located in close proximity to the BGP gene on the long arm of chromosome 19 (10, 35) , it is improbable that major deletions are the reason for the loss or reduction of BGP expression. Furthermore, gross alterations of chromosome 19 are not frequently encountered in colorectal carcinomas (36) . At this point, we propose two alternative mechanisms that could account for the observed inverse relation of BGP and NCA expression in colorectal cancer (Fig. 5) . During malignant transformation, the expression of BGP may be lost due to methylation of the BGP promoter. For a potential common transcription factor, this may exert a positive dose effect on NCA expression. Alternatively, BGP may be lost because of the down-regulation of a BGP-promoting trans-acting factor that acts as a repressor for NCA under normal conditions. Studies on the regulation of BGP expression may help to explain the basis of altered morphology and invasive potential of colorectal cancer. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Wa 473/5-1) and from the Fritz Thyssen Stiftung.
